Defiance ETFs’s Gilead Sciences GILD Stock Holding History

Defiance ETFs’s Portfolio GILD Stock Details GILD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$641K	Buy	5,089 +944	+23%	+$124K	0.01%	264
2026 Q1	$578K	Buy	+4,145	New	+$580K	0.01%	256

Other funds holding GILD

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Defiance ETFs's GILD Position: Q2 2026 in Review

Defiance ETFs increased its Gilead Sciences (GILD) stake by 23% in Q2 2026, buying an estimated $124K and bringing the position to 5,089 shares worth $641K. The position accounts for 0.01% of the portfolio, ranked #264.

Defiance ETFs first reported a position in GILD in Q1 2026 and has held it in 2 quarters since. 2,268 funds tracked by Wall St. Rank hold GILD as of Q2 2026.

Defiance ETFs held 5,089 shares of Gilead Sciences worth $641K as of Q2 2026.
Defiance ETFs bought 944 Gilead Sciences shares in Q2 2026, an estimated $124K.
Gilead Sciences made up 0.01% of Defiance ETFs's portfolio in Q2 2026, its #264 holding.
Defiance ETFs first reported a position in Gilead Sciences in Q1 2026 and has held it in 2 quarters since.
2,268 funds tracked by Wall St. Rank held Gilead Sciences as of Q2 2026.

Based on Defiance ETFs's 13F filing for Q2 2026, filed 14 Aug 2026.